Adam Margolin is the co-founder and CEO of NextVivo, a company specializing in air-liquid interface (ALI) organoid technology. NextVivo's approach allows tissue organoids to grow in 3D using ALI, overcoming challenges faced by other organoid technologies that rely on hypoxic environments. Dr. Margolin left his academic career, including leadership roles at Mount Sinai and Sema4, to pursue the potential of NextVivo. He is recognized internationally for his expertise in data science and cancer research, with numerous funded projects and influential contributions to computational biology. He completed his postdoctoral research at the Broad Institute and holds advanced degrees from Columbia University and the University of Pennsylvania.